drugset / Trial / NCT02699710

Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects

NCT02699710

Phase 1 Completed 50 enrolled Genentech, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a Phase I, single center, randomized (Parts 1 and 2 only), open-label, 3 part study. Parts 1 and 2 are 2-way crossover, with 1-fixed sequence, 3-period designs to investigate the effect of formulation, food and rabeprazole on the PK of GDC-0853 in healthy male and female (of non-childbearing potential) participants. Part 3 is a fixed-sequence study with 3 treatments to characterize the steady-state PK of the GDC-0853 tablet; the effect of simultaneous administration of a single dose of methotrexate on the steady-state kinetics of GDC-0853; and the effect of dosing GDC-0853 to steady-state on the single dose PK of methotrexate in healthy male participants.

Timeline

Start
2015-09-03
Primary completion
2016-05-26
Completion
2016-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenebrutinib Small molecule 200 mg Oral
Subject Methotrexate Small molecule 7.5 mg Oral
Background Rabeprazole Small molecule 20 mg Oral
Background folic acid Other / unclassified 5 mg Oral

Indications

No indication recorded.